Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.

Kvols LK, Oberg KE, O'Dorisio TM, Mohideen P, de Herder WW, Arnold R, Hu K, Zhang Y, Hughes G, Anthony L, Wiedenmann B.

Endocr Relat Cancer. 2012 Sep 14;19(5):657-66. doi: 10.1530/ERC-11-0367. Print 2012 Oct.

2.

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.

Wolin EM, Jarzab B, Eriksson B, Walter T, Toumpanakis C, Morse MA, Tomassetti P, Weber MM, Fogelman DR, Ramage J, Poon D, Gadbaw B, Li J, Pasieka JL, Mahamat A, Swahn F, Newell-Price J, Mansoor W, Öberg K.

Drug Des Devel Ther. 2015 Sep 3;9:5075-86. doi: 10.2147/DDDT.S84177. eCollection 2015.

3.
4.

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ, Melmed S, Biller BM; Pasireotide Acromegaly Study Group..

J Clin Endocrinol Metab. 2010 Jun;95(6):2781-9. doi: 10.1210/jc.2009-2272. Epub 2010 Apr 21.

PMID:
20410233
5.

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers.

Golor G, Hu K, Ruffin M, Buchelt A, Bouillaud E, Wang Y, Maldonado M.

Drug Des Devel Ther. 2012;6:71-9. doi: 10.2147/DDDT.S29125. Epub 2012 Apr 19.

6.
7.

Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors.

Chan JA, Ryan DP, Zhu AX, Abrams TA, Wolpin BM, Malinowski P, Regan EM, Fuchs CS, Kulke MH.

Endocr Relat Cancer. 2012 Sep 14;19(5):615-23. doi: 10.1530/ERC-11-0382. Print 2012 Oct.

8.

Pasireotide (SOM230): development, mechanism of action and potential applications.

Schmid HA.

Mol Cell Endocrinol. 2008 May 14;286(1-2):69-74. Epub 2007 Sep 19. Review.

PMID:
17977644
9.

Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.

Cives M, Kunz PL, Morse B, Coppola D, Schell MJ, Campos T, Nguyen PT, Nandoskar P, Khandelwal V, Strosberg JR.

Endocr Relat Cancer. 2015 Feb;22(1):1-9. doi: 10.1530/ERC-14-0360. Epub 2014 Nov 6.

10.

Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study.

Horsmans Y, Hu K, Ruffin M, Wang Y, Song D, Bouillaud E, Wang Y, Mazur D, Botha FP, Heuman DM.

J Clin Pharmacol. 2012 Apr;52(4):552-8. doi: 10.1177/0091270011400072. Epub 2012 Jan 26.

PMID:
22282526
11.

Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.

Anthony L, Vinik AI.

Pancreas. 2011 Oct;40(7):987-94. doi: 10.1097/MPA.0b013e31821f66b4.

PMID:
21697761
12.

Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.

Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J, Caplin ME.

Aliment Pharmacol Ther. 2009 Oct;30(7):733-40. doi: 10.1111/j.1365-2036.2009.04083.x. Epub 2009 Jul 2.

13.

Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.

Petersenn S, Bollerslev J, Arafat AM, Schopohl J, Serri O, Katznelson L, Lasher J, Hughes G, Hu K, Shen G, Reséndiz KH, Giannone V, Beckers A.

J Clin Pharmacol. 2014 Nov;54(11):1308-17. doi: 10.1002/jcph.326. Epub 2014 May 24.

PMID:
24800725
14.

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.

Bronstein MD, Fleseriu M, Neggers S, Colao A, Sheppard M, Gu F, Shen CC, Gadelha M, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Freda P; Pasireotide C2305 Study Group..

BMC Endocr Disord. 2016 Apr 2;16:16. doi: 10.1186/s12902-016-0096-8.

15.

Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study.

Beglinger C, Hu K, Wang Y, Bouillaud E, Darstein C, Wang Y, Mohideen P.

Endocrine. 2012 Oct;42(2):366-74. Epub 2012 Apr 21.

PMID:
22527887
16.
17.

Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.

Oberg K.

Expert Rev Anticancer Ther. 2009 May;9(5):557-66. doi: 10.1586/era.09.26. Review.

PMID:
19445573
18.

Effects of somatostatin analogs on glucose homeostasis in rats.

Schmid HA, Brueggen J.

J Endocrinol. 2012 Jan;212(1):49-60. doi: 10.1530/JOE-11-0224. Epub 2011 Oct 10.

19.

Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.

Petersenn S, Unger N, Hu K, Weisshaar B, Zhang Y, Bouillaud E, Reséndiz KH, Wang Y, Mann K.

J Clin Pharmacol. 2012 Jul;52(7):1017-27. doi: 10.1177/0091270011408727. Epub 2011 Jun 14.

PMID:
21673137
20.

Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer.

Suleiman Y, Mahipal A, Shibata D, Siegel EM, Jump H, Fulp WJ, Springett GM, Kim R.

Cancer Chemother Pharmacol. 2015 Sep;76(3):481-7. doi: 10.1007/s00280-015-2814-8. Epub 2015 Jul 1.

PMID:
26126727

Supplemental Content

Support Center